Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.48 |
| ▸ | TGM2 | P21980 | 3/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21275401 | 0.89 | MAPT (0.63) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL29608091 | 0.83 | MAPT (0.67) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL611726 | 0.83 | MAPT (0.67) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL17108488 | 0.81 | MAPT (0.63) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL21245799 | 0.81 | MAPT (0.63) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL1393986 | 0.81 | MAPT (0.63) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL1645884 | 0.80 | MAPT (0.62) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL17055029 | 0.80 | MAPT (0.62) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL1991089 | 0.80 | MAPT (0.62) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 | |
| SCHEMBL29437382 | 0.80 | MAPT (0.62) | MAPTPOLBSMN1; SMN2RAB9ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476275-B2 | N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-1613596-B1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-7320979-B2 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | ABBOTT GMBH & CO. KG (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. | 2006-07-20 | — | — | US | disclosed |
| EP-1613596-A1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089905-A1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204422-A1 | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204422-A1 | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds | CBR1, CBR3, CNR2 | MAPT 4659/4885POLB 3359/4885SMN1; SMN2 2287/4885 |
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | DRD2, DRD3, TACR1 | MAPT 4633/4885POLB 4202/4885SMN1; SMN2 3882/4885 |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | PTGDR, TACR1, TACR2 | MAPT 4631/4885POLB 4486/4885SMN1; SMN2 3817/4885 |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | CBR3, CNR2, CNR1 | MAPT 4677/4885POLB 4090/4885SMN1; SMN2 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.